Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Non-cash Items (2016 - 2024)

Historic Non-cash Items for CytomX Therapeutics (CTMX) over the last 11 years, with Q4 2024 value amounting to $5.5 million.

  • CytomX Therapeutics' Non-cash Items fell 3657.76% to $5.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $5.5 million, marking a year-over-year decrease of 3657.76%. This contributed to the annual value of $5.5 million for FY2024, which is 3657.76% down from last year.
  • As of Q4 2024, CytomX Therapeutics' Non-cash Items stood at $5.5 million, which was down 3657.76% from $8.7 million recorded in Q4 2023.
  • In the past 5 years, CytomX Therapeutics' Non-cash Items registered a high of $23.6 million during Q4 2021, and its lowest value of $5.3 million during Q1 2021.
  • Its 5-year average for Non-cash Items is $9.4 million, with a median of $6.2 million in 2020.
  • Its Non-cash Items has fluctuated over the past 5 years, first soared by 28516.63% in 2020, then tumbled by 6851.98% in 2022.
  • CytomX Therapeutics' Non-cash Items (Quarter) stood at $23.2 million in 2020, then rose by 1.72% to $23.6 million in 2021, then crashed by 68.52% to $7.4 million in 2022, then increased by 16.73% to $8.7 million in 2023, then tumbled by 36.58% to $5.5 million in 2024.
  • Its Non-cash Items stands at $5.5 million for Q4 2024, versus $8.7 million for Q4 2023 and $7.4 million for Q4 2022.